The Acetyl CoA Carboxylase 2 pipeline drugs market research report outlays comprehensive information on the Acetyl CoA Carboxylase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Acetyl CoA Carboxylase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Central Nervous System, Oncology, and Genetic Disorders which include the indications Type 2 Diabetes, Insulin Resistance, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Breast Cancer, Hepatocellular Carcinoma, and Charcot-Marie-Tooth Disease. It also reviews key players involved in Acetyl CoA Carboxylase 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Acetyl CoA Carboxylase 2 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, and Preclinical stages are 1, 1, and 3 respectively.
Acetyl CoA Carboxylase 2 overview
Acetyl-CoA Carboxylase 2 (ACC2) is a key enzyme involved in fatty acid metabolism, playing a central role in the regulation of lipid homeostasis within cells. ACC2 is primarily found in mitochondria and is crucial for controlling the balance between fatty acid synthesis and fatty acid oxidation. ACC2, along with its cytosolic counterpart ACC1, catalyses the carboxylation of acetyl-CoA to malonyl-CoA, a crucial step in the de novo synthesis of fatty acids. ACC2 is particularly important in tissues with high energy demands, such as skeletal muscle and the heart, where it helps coordinate the utilization of fatty acids for energy production. Its role in regulating fatty acid oxidation positions ACC2 as a potential target for interventions aimed at modulating lipid metabolism in the context of metabolic diseases, including obesity and insulin resistance.
For a complete picture of Acetyl CoA Carboxylase 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
